NeoVisc® is a 1.0% solution of a highly purified, linear high molecular weight sodium hyaluronate which is derived entirely from non-animal sources. NeoVisc® has been clinically available in Canada since 1977. Patients with Osteoarthritis typically experience pain and loss of mobility because of changes to the internal environment of the affected joint. NeoVisc® works as a viscosupplement by improving the natural viscosity and elasticity of synovial fluid, thereby increasing lubrication, improved joint mobility, and a reduction in pain. NeoVisc® is administered by a physician through a series of intraarticular injections (injections into the synovial space of the joint). Onset of symptomatic relief varies from patient to patient depending on the severity of the patients’ s Oseoarthritis.